Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns

Autolus Therapeutics plc

Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.
In Feb 2024, closed BioNTech collaboration ($250M upfront) and $350M ADS offering for $600M gross proceeds to fund obe-cel launch.
BLA for obe-cel in r/r adult B-ALL submitted to FDA; PDUFA target action date Nov 16, 2024; MAA submitted to EMA.
CDO Dr. Edgar Braendle resigns effective March 2024; will consult. Chris Williams promoted to CBO, Alex Driggs to SVP Legal.
Obe-cel Phase 1 SLE trial open for enrollment; initial data expected late 2024; Nucleus manufacturing facility obtained MIA for commercial supply.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Autolus Therapeutics plc reported financial results for the full year ended December 31, 2023.

Period: the full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, Autolus Therapeutics plc (the “ Company ”) issued a press release announcing its recent business highlights and financial results for year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-24-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.